ARGX (argenx SE) Valuation Rank


ARGX argenx SE ARGX
78 GF Score
Price $944.48
GF Value $1,399.78
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is argenx SE Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

argenx SE Valuation Rank Related Terms

ARGX
78GF Score
argenx SE ARGX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is argenx SE (ARGX) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of $944.48 is trading 32.5% below its estimated GF Value™ of $1,399.78. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for ARGX:

  • Valuation Rank:
  • GF Value™: $1,399.78 vs. price of $944.48 (32.5% below fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score

Get the complete analysis for ARGX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$944.48
Price
$1,399.78
GF Value